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Background. 131I-Metaiodobenzylguanidine (131I-MIBG) pro-
vides targeted radiotherapy for children with neuroblastoma, a
malignancy of the sympathetic nervous system. Dissociated radioac-
tive iodide may concentrate in the thyroid, and 131I-MIBG is
concentrated in the liver after 131I-MIBG therapy. The aim of our
study was to analyze the effects of 131I-MIBG therapy on thyroid and
liver function. Procedure. Pre- and post-therapy thyroid and liver
functions were reviewed in a total of 194 neuroblastoma patients
treated with 131I-MIBG therapy. The cumulative incidence over time
was estimated for both thyroid and liver toxicities. The relationship
to cumulative dose/kg, number of treatments, time from treatment to
follow-up, sex, and patient age was examined. Results. In patients
who presented with Grade 0 or 1 thyroid toxicity at baseline,
12 ± 4% experienced onset of or worsening to Grade 2 hypothy-
roidism and one patient developed Grade 2 hyperthyroidism by 2
years after 131I-MIBG therapy. At 2 years post-131I-MIBG therapy,
76 ± 4% patients experienced onset or worsening of hepatic toxic-
ity to any grade, and 23 ± 5% experienced onset of or worsening
to Grade 3 or 4 liver toxicity. Liver toxicity was usually transient
asymptomatic transaminase elevation, frequently confounded by dis-
ease progression and other therapies. Conclusion. The prophylactic
regimen of potassium iodide and potassium perchlorate with 131I-
MIBG therapy resulted in a low rate of significant hypothyroidism.
Liver abnormalities following 131I-MIBG therapy were primarily
reversible and did not result in late toxicity. 131I-MIBG therapy is a
promising treatment for children with relapsed neuroblastoma with
a relatively low rate of symptomatic thyroid or hepatic dysfunction.
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INTRODUCTION
Neuroblastoma, the most common extra-cranial solid tumor in
children, is an embryonal tumor derived from the peripheral sym-
pathetic nervous system. It is highly malignant, with metastatic
disease at diagnosis in half of cases. Despite improvement in out-
come with intensification therapy and treatment of minimal residual
disease, 15% of patients have disease that is refractory to induction
chemotherapy, and more than 50% of patients who achieve initial
remission ultimately relapse and die as a result of their disease [1].
Metaiodobenzylguanidine (MIBG) is a guanethidine derivative
and analogue of norepinephrine with specific affinity for neural
crest tissues. When labeled with iodine-131 (131I-MIBG), MIBG
has shown activity against neuroblastoma, with response rates for
refractory disease varying from 20% to 37% [2–10]. In a Phase
II clinical trial of 164 patients, the response rate (complete and
partial) for all patients was 36% [2]. While 131I-MIBG has typi-
cally been used as a single agent in relapsed disease, several groups
have increasingly used 131I-MIBG alone earlier in the course of dis-
ease or combined with chemotherapy [11–16]. With this expanding
role, an understanding of the late toxicity of 131I-MIBG has become
increasingly important.
The most common toxicities associated with high-dose 131I-
MIBG targeted radiotherapy are primarily hematologic, with almost
all patients requiring at least one platelet or red cell transfusion
and with most patients developing neutropenia. Approximately
36% of patients also require autologous hematopoietic stem-cell
rescue (ASCR) after 131I-MIBG treatment [17]. The chief non-
hematological toxicities reported with 131I-MIBG therapy include
transient nausea and vomiting, sialoadenitis, transient hepatic abnor-
malities, later adrenal insufficiency (<1%), and variable rates of
hypothyroidism [18–24]. Secondary malignancies such as acute
myelogenous leukemia and myelodysplastic syndrome have also
been reported in 3–5% of children who have received 131I-MIBG
therapy to treat relapsed or refractory neuroblastoma [2,25,26].
Thyroid function and liver function after 131I-MIBG therapy are
of particular interest because the radioactivity is often concentrated
in these organs. Both the thyroid and the liver can be visualized
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on the 96 hr post infusion 131I-MIBG scan after 131I-MIBG ther-
apy and the dissociated anion may be specifically concentrated in
the thyroid. However, limited data are available to assess the acute
and late effects of 131I-MIBG therapy on thyroid and liver func-
tion. Reports of hypothyroidism following 131I-MIBG therapy have
been highly variable, with incidence rates ranging from 15% to
64% of patients. There has also been little systematic examination
and no reports of late liver dysfunction associated with 131I-MIBG
therapy [19–23].
We report here an analysis of thyroid and liver function for neu-
roblastoma patients with follow-up data after receiving therapy with
131I-MIBG. We examined the relationship between liver and thyroid
toxicity incidence and cumulative 131I-MIBG dose/kg, number of
treatments, sex, and patient age at the time of therapy. We also ana-
lyzed the relation of thyroid dysfunction with thyroid visualization
on post-therapy 96 hr scans.
METHODS
Study Subjects
All evaluated patients either failed to achieve partial or complete
response with standard induction therapy or developed progressive
disease at any time prior to 131I-MIBG therapy. All patients had
demonstrated 131I-MIBG uptake in skeletal or soft tissue prior to
treatment. The vast majority of patients were heavily pre-treated,
with a median of three prior regimens, and almost all had prior radia-
tion therapy and surgery. All patients had total bilirubin ≤2× normal
for age and aspartate transaminase (AST) and alanine transaminase
(ALT) <5× normal for age. All patients were fully recovered from
the toxic effects of prior therapy.
Eligibility for inclusion in this analysis included evaluation of
baseline thyroid and liver function and at least one post-therapy
value for thyroid function tests (thyroid stimulating hormone (TSH),
free T4, or T4) and/or liver function tests (AST, ALT, total biliru-
bin). Patients were enrolled on therapeutic trials with 131I-MIBG,
and appropriate informed consent was obtained for all patients with
approval by the institutional human research review board and radi-
ation safety committee at treating institutions.
Treatment
Patients were treated between August 30, 1996 and May 1, 2008
on six clinical trials using 131I-MIBG therapy. These studies included
patients from the following clinical trials: a multi-institutional
Phase II study of 18 mCi/kg [2], an ongoing UCSF compassionate
use study of 131I-MIBG, NANT 99–01—a Phase I study of 131I-
MIBG with myeloablative chemotherapy [11], NANT 2000–01—a
double infusion of 131I-MIBG (24–42 mCi/kg) [27], NANT 2001–
02—131I-MIBG (12 mCi/kg) with myeloablative chemotherapy, and
NANT 2004–06—irinotecan and vincristine with 131I-MIBG (8–
15 mCi/kg) (www.nant.org).
The 131I-MIBG for the studies was supplied either by the Michi-
gan Memorial Phoenix Laboratory at the University of Michigan
(Investigational New Drug 17,239; Ann Arbor, MI), Draximage
Radiopharmaceuticals (Investigational New Drug 76,227; Kirk-
land, Quebec, Canada), or the University of California at San
Francisco (Investigational New Drug 32,147; San Francisco, CA).
Patients received 131I-MIBG infusions at the University of Califor-
nia, San Francisco, Children’s Hospital of Philadelphia, University
of Michigan, and Cincinnati Children’s Hospital Medical Center.
All 131I-MIBG products had a free iodide content of <5%. Patients
who were treated on NANT 99–01, NANT 2001–02, and NANT
2004–06 received chemotherapy in combination with 131I-MIBG
therapy and were therefore excluded from liver function analyses.
Patients were treated with 1–3 therapeutic doses of 131I-MIBG,
given intravenously over 1–2 hr with hydration and a Foley catheter
for bladder protection. All patients remained in radiation-protected
isolation for 2–7 days until radiation emissions met institutional
regulations. The dose of radiation to the whole body from 131I-MIBG
was calculated for every patient using multiple measurements from
a hand-held or ceiling-mounted Geiger counter [28].
Thyroid Protection
To protect the thyroid from any dissociated 131-iodide from the
therapeutic doses of 131I-MIBG, patients were given an oral loading
dose of 6 mg/kg of KI solution 8–12 hr prior to 131I-MIBG infusion,
then 1 mg/kg every 4 hr on days 0–6, and 1 mg/kg/day through day
45 post-infusion. Potassium perchlorate was also given as an addi-
tional oral blocking agent for 5 days post-infusion with a loading
dose of 8 mg/kg, then 2 mg/kg every 6 hr on days 0–4, beginning
4 hr after the start of 131I-MIBG infusion.
Monitoring
Patients on all studies were monitored weekly for a minimum of
6 weeks or until recovery from toxicity. Tumor response evaluations
and hematologic, hepatic, renal, and endocrine toxicity evaluations
were required at 3-month intervals for 1 year, then every 6 months,
or until the patient died or went on to other therapy. Baseline abnor-
malities were noted if available.
Scan Review
A post-infusion 131I-MIBG scan (median time of 96 hr post-
infusion (range: 72–120 hr)) was performed for all patients receiving
131I-MIBG therapy. Post-therapy scans were reviewed by a nuclear
medicine radiologist at the University of California, San Francisco
for thyroid visualization. 131I-MIBG uptake in the thyroid was semi-
quantitatively scored using a point scale: 0 = no uptake, 1 = faint
uptake, 2 = definite uptake, 3 = intense uptake. For patients who
had more than one scan available, the scan with the highest review
assessment was used in the analyses.
Evaluation of Thyroid Dysfunction at Baseline and
After 131I-MIBG Therapy
Pre- and post-therapy TSH and T4 (free T4 when available)
values were collected from medical records. Any symptomatology
and/or use of thyroid hormone replacement therapy were noted.
Abnormal thyroid function at baseline or time points after 131I-
MIBG treatment was defined as TSH and/or T4 concentrations
outside of the institutional normal ranges or if patients were noted to
be receiving thyroid hormone replacement therapy at that time. Tox-
icity grade was determined based on CTC v3.0. For TSH and T4 lab
values that did not have normal ranges, national age and sex-adjusted
normal ranges were used. If one of the two thyroid function mea-
sures was not available for a particular time point, only the available
measure was evaluated for thyroid function. This type of missing
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data was very limited, and treating missing TSH or T4 values as
normal did not significantly influence the results of the analyses.
Evaluation of Liver Dysfunction at Baseline and After
131I-MIBG Therapy
Liver function tests, including AST, ALT, and total bilirubin,
were closely monitored and recorded pre-therapy and then weekly
for the first 6 weeks after therapy and repeated at 3-month intervals
for 1 year, then every 6 months, or until the patient died or went
on to other therapy. Pre- and post-therapy liver functions were col-
lected and hepatic toxicity was compared to the institutional normal
ranges and graded using CTC v2.0 or CTC v3.0 per study protocol.
If a normal range at a time point was missing for a patient, the nor-
mal range from another time point for the same patient was used,
considering that the normal ranges were very similar across different
time points. If one or two of the three liver function measures were
not available for a particular time point, only the available measures
were evaluated for liver toxicity. This type of missing data was lim-
ited, and treating missing lab values as normal did not significantly
influence the results of the analyses.
Statistical Methods
The cumulative incidence function over time was estimated for
both thyroid and liver toxicities [29]. In the analysis of the thyroid
data, we evaluated (a) the onset or worsening of thyroid toxicity to
Grade 2 (the highest grade of thyroid toxicity in our data) after 131I-
MIBG therapy and (b) the onset or worsening of thyroid toxicity
to any grade (Grade 1 or 2) after 131I-MIBG treatment. In (a), a
change from baseline Grade 0 or 1 to Grade 2 thyroid toxicity post-
131I-MIBG therapy was considered an event. In (b), a change from
baseline Grade 0 to Grade 1 or 2 after 131I-MIBG treatment, or a
change from baseline Grade 1 to Grade 2 after 131I-MIBG treatment
was considered an event. Patients who did not experience events
defined above were censored at the time of the last test date. Patients
with Grade 2 thyroid abnormality at baseline were excluded from
the cumulative incidence analysis because medical management of
thyroid abnormality made it unlikely for these patients to experience
a further worsening of thyroid function after 131I-MIBG treatment.
Similarly, in the analysis of the liver data, we evaluated (a) the onset
or worsening of liver toxicity to Grade 3 and 4 after 131I-MIBG
treatment and (b) the onset or worsening of liver toxicity to any
grade (Grade 1, 2, 3, or 4). In (a), a change from baseline Grade 0,
1, or 2 liver abnormality to Grade 3 or 4 after 131I-MIBG therapy
was considered an event, and in (b), a change from baseline Grade
0 to Grade ≥1, or a change from baseline Grade 1 to Grade ≥2,
or a change from baseline Grade 2 to Grade ≥3 was considered an
event. Patients who did not experience an event defined above were
censored at the time of the last test date. The “time 0” reference for
all cumulative incidence analysis was the date of the first 131I-MIBG
treatment.
Analysis of toxicity cumulative incidence and its dependence
on patient and disease characteristics was based on the log-rank
test, product-limit (Kaplan–Meier) estimator, and univariate and
multivariate Cox regression analysis [30]. The cumulative dose of
131I-MIBG/kg was included as a time-dependent covariate in the Cox
regression analysis. Missing data for variables used in multivariate
analysis were included in the models as a “missing” category. All P-
values are two-sided. Estimates of hazard ratio are presented with
95% confidence intervals. Statistical computation was performed
using Stata 9.2 [31].
RESULTS
Analysis Cohort
A total of 194 patients were reviewed for thyroid and liver func-
tion. Of these patients, 160 had documented thyroid function values
before and after 131I-MIBG therapy and were evaluable for thyroid
toxicity, and 136 had documented liver function values before and
after 131I-MIBG therapy and were evaluable for liver toxicity (Table
I). Thyroid and liver data were both available in 102 patients.
Table I, patient characteristics, shows that this was a heavily
pre-treated group of patients, and that approximately 25% of them
had more than one 131I-MIBG therapy. The median cumulative
131I-MIBG dose was 18.2 mCi/kg (range: 5.0, 54.2). The median
time to the last follow-up thyroid function test was 3.5 months, but
36 patients had follow-up thyroid function test results that were
obtained 12 months or more after 131I-MIBG therapy. Thirty-eight
(24%) patients presented with abnormal thyroid function values at
baseline, including one patient with an X-linked TBG deficiency
that pre-disposed him to hypothyroidism, and seven patients who
were on L-thyroxine prior to receiving 131I-MIBG therapy. Among
the 136 patients evaluable for liver toxicity, the distribution of age,
sex, the number of prior regimens, and cumulative 131I-MIBG dose
was very similar to that with thyroid data (Table I). Thirty-eight
(28%) patients showed baseline liver function abnormality.
Thyroid Abnormalities Following 131I-MIBG Therapy
Of the 160 patients evaluable for thyroid function following
131I-MIBG therapy, 7 patients had Grade 2 thyroid toxicity at base-
line and remained Grade 2 after 131I-MIBG treatment. Thirty-one
had Grade 1 abnormalities at baseline, and of these, 6 progressed
to Grade 2 hypothyroidism, and 14 normalized without interven-
tion. Of the 122 patients with normal baseline thyroid function, 3
developed Grade 2 hypothyroidism and 1 patient developed Grave’s
disease and had subsequent thyroidectomy. In all, 36 patients
experienced an onset or worsening of thyroid function tests after 131I-
MIBG therapy, including 9 who developed Grade 2 hypothyroidism
requiring treatment with L-thyroxine (Fig. 1).
Table II and Figure 2A summarize cumulative incidence of onset
or worsening of thyroid toxicities after 131I-MIBG therapy and its
relationship with other factors. The seven patients who had Grade
2 thyroid function abnormality at baseline were excluded from the
cumulative incidence analysis. In the remaining patients, 15 ± 5%
experienced onset of or worsening to Grade 2 hypothyroidism or
hyperthyroidism by 2 years after 131I-MIBG treatment, and 40 ± 7%
of patients experienced onset or worsening of any grade (Fig. 2A).
In univariate and multivariate Cox regression analyses, the risk of
Grade 2 toxicity was significantly higher in patients with baseline
Grade 1 thyroid abnormality compared to those with normal baseline
thyroid function (Table II). The 2-year cumulative incidence rates
in these two groups were 35 ± 14% and 10 ± 5%, respectively. In
the analyses of onset or worsening of any grade thyroid toxicity,
there was no significant association with baseline thyroid function.
Age, sex, the number of previous chemotherapy and biotherapy reg-
imens, thyroid uptake, and cumulative 131I-MIBG dose did not have
a significant impact on thyroid toxicity.
Pediatr Blood Cancer DOI 10.1002/pbc
194 Quach et al.
TABLE I. Characteristics of Patients With Thyroid and/or Liver Data
Patient characteristicsa Thyroid, all patients (N = 160) Liver, all patients (N = 136)
Age at study entry (years)
Median (range) 6.8 (1.5–30.2) 6.9 (1.4–30.2)
<12 127 (79%) 109 (80%)
12–21 29 (18%) 24 (18%)
>21 4 (3%) 3 (2%)
Sex
Males 101 (63%) 82 (60%)
Females 59 (37%) 54 (40%)
Number of prior regimens
Median (range) 3 (1–11) 3 (1–11)
1 11 (7%) 6 (5%)
2 43 (27%) 22 (16%)
3 45 (28%) 44 (32%)
4 22 (14%) 25 (18%)
5–11 39 (24%) 39 (29%)
131I-MIBG Clinical Trial (number of patients evaluated)
Phase II 131I-MIBG, compassionate use 131I-MIBG (131I-MIBG alone) 99 (62%) 116 (85%)
NANT 99–01, NANT 2001–02 (131I-MIBG + CEM + AHSCT) 33 (21%) —
NANT 2000–01 (rapid double sequence 131I-MIBG) 19 (12%) 20 (15%)
NANT 2004–06 (131I-MIBG + irinotecan + vincristine) 9 (5%) —
Number of 131I-MIBG treatments
1 treatment (%) 121 (76%) 106 (78%)
2 treatments (%) 32 (20%) 25 (18%)
3 treatments (%) 7 (4%) 5 (4%)
Cumulative 131I-MIBG dose/kg (mCi)
Median (range) 18.2 (5.0–54.2) 18.5 (6.3–54.2)
Length of time from treatment to furthest follow-up (months)
Median (range) 3.5 (0.8–88.2) 7.4 (0.1–90.5)
<3 months 75 (47%) 40 (29%)
≥3 to <6 months 25 (16%) 20 (15%)
≥6 to <12 months 24 (15%) 27 (20%)
≥12 to <24 months 12 (7%) 20 (15%)
≥24 months 24 (15%) 29 (21%)
Patients with baseline abnormalities
Yes 38 (24%) 38 (28%)
No 122 (76%) 98 (72%)
Thyroid uptake seen on post-96 hr 131I-MIBG scan
None 54 (52%) —
Faint 20 (19%) —
Definite 25 (24%) —
Strong 5 (5%) —
Not evaluable 11 —
Missing/no scan 45 —
aOne hundred ninety-four total individual patients reviewed; 102 patients had both thyroid and liver data. Evaluable patients for liver and thyroid
toxicity evaluations were those with submitted laboratory values. Patients who did not have submitted thyroid and/or liver data either died <3
months after receiving 131I-MIBG therapy, started new therapy <3 months after receiving 131I-MIBG therapy, or were lost to follow-up. Only
patients who received 131I-MIBG therapy alone, without chemotherapy, were evaluable for liver toxicity.
Analysis of the cumulative incidence of hypothyroidism alone
after 131I-MIBG therapy showed that at 2 years after treatment,
32 ± 6% of patients experienced an onset or worsening of any
grade hypothyroidism, and 12 ± 4% had experienced onset of or
worsening to Grade 2 hypothyroidism.
Liver Function Following 131I-MIBG Therapy
Out of the 136 patients with documented liver function values fol-
lowing 131I-MIBG therapy, 98 had normal liver function at baseline,
of whom 20 remained normal after 131I-MIBG therapy, 14 experi-
enced Grade 3 or 4 hepatic toxicities, and 64 experienced Grade 1
or 2 toxicity after treatment. Thirty-eight patients had Grade 1 or
2 liver toxicity at baseline, of whom 7 worsened to Grade 3 or 4
after 131I-MIBG therapy, 7 worsened from Grade 1 to Grade 2, 17
remained the same grade, 1 decreased from Grade 2 to Grade 1, and
6 normalized without intervention. No patient had Grade 3 or 4 liver
abnormalities at baseline. Of the 136 patients, a total of 18 patients
experienced Grade 3 elevation of at least one measure, and a total
of 3 patients experienced Grade 4 elevations (Table III).
At 2 years post-131I-MIBG therapy, 76 ± 4% patients had expe-
rienced onset or worsening of hepatic toxicities to any grade (Grade
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Fig. 1. Flowchart of all patients with pre- and post-therapy thyroid data. 1Two patients had elevated T4 only, and one patient had both elevated
T4 and low TSH. 2This patient had Grade 1 low TSH only at baseline, but devloped Grade 1 hypothyroidism after 131I-MIBG treatment. 3One
pateint had elevated T4 only and one patient had both elevated T4 and low TSH. 4Of these patients, nine developed compensated hypothyroidism.
5Of these patients, three developed compensated hypothyroidism.
1, 2, 3, or 4) (Fig. 2B). Most of these toxicities were of Grade 1 or 2.
23 ± 5% of patients had experienced onset of or worsening to Grade
3 and 4 liver toxicity (Fig. 2B). Table IV summarizes the relationship
between cumulative incidence of onset or worsening of liver toxici-
ties after 131I-MIBG treatment and the other factors among patients
reviewed for liver function. In Cox regression analysis, there was no
significant association between baseline liver function and the risk
of Grade 3 or 4 liver toxicity (Table IV). However, there was a sig-
nificant association between baseline liver functioning and onset or
worsening of any grade liver toxicity. Patients with abnormal liver
function at baseline had a significantly lower risk of progressing to
a higher grade toxicity than patients with normal liver function at
baseline (P < 0.0001 in both the univariate and multivariate anal-
yses; Table IV). By 2 years after 131I-MIBG treatment, 84 ± 4%
of patients with normal liver function at baseline and 48 ± 10% of
patients with abnormal liver function at baseline had progressed to
higher grade toxicity. The above results indicated that the risk of
worsening to Grade 3 or 4 liver toxicity post-131I-MIBG treatment
was similar between patients with normal (Grade 0) or abnormal
(Grade 1 or 2) baseline liver function, but the risk of worsening into
Grade 1 or 2 after 131I-MIBG treatment for patients who were nor-
mal at baseline was higher than the risk of worsening into Grade
2 for patients who had Grade 1 liver abnormality at baseline. Age,
gender, and the number of previous chemotherapy or biotherapy
regimens were not significantly associated with onset of or wors-
ening to Grade 3 and 4 or onset or worsening of any grade hepatic
toxicity. However, cumulative 131I-MIBG dose showed a trend to be
associated with onset or worsening of liver toxicities of any grade
(P = 0.079 in the univariate analysis and was significantly associated
(P = 0.027) in the multivariate analysis), but it was not associated
with incidence of Grade 3 and 4 hepatic toxicity.
Of the 21 patients who had Grade 3 or 4 hepatic toxicities
after 131I-MIBG therapy, only 8 were considered to be possibly
related to the 131I-MIBG therapy; the remainder were coded as
“unlikely.” For these eight patients, the median follow-up time to
the date of first abnormality was 1 month (range: 0.5–9 months).
All abnormal values returned to normal after a median time of
15 days (Table III). The Grade 3 or 4 toxicities for the remain-
ing 13 patients were deemed to be unlikely related to the 131I-MIBG
therapy (Table III). The recorded abnormal post-therapy values for
those 13 patients occurred at a median time of 6 months (range:
2–44 months) after 131I-MIBG therapy. The factors that probably
contributed towards the occurrence of the Grade 3 or 4 liver toxi-
cities among those 13 patients included: other subsequent therapy
for neuroblastoma (N = 4), active infections (N = 2), progressive
disease (N = 3), or progressive disease and other therapy (N = 4).
Other therapies included hu14.18-IL2, myeloablative chemotherapy
in preparation for hematopoietic cell transplant, and 13-cis-retinoic
acid [32].
DISCUSSION
This large follow-up study including 194 patients after 131I-
MIBG therapy shows that with proper preventive therapy, damage to
the thyroid gland is uncommon and rarely clinically significant. Per-
manent serious damage to the liver was not evident; most changes
Pediatr Blood Cancer DOI 10.1002/pbc
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Fig. 2. Cumulative incidence of increased thyroid and liver toxicity
after 131I-MIBG treatment (see the Statistical Methods Section). A: Soild
line is cumulative incidence of onset of or worsening to Grade 2 thyroid
toxicity compared to baseline. Dashed line is cumulative incidence of
onset of or worsening to either Grade 1 or 2 thyroid toxicity compared to
baseline. B: Solid line is cumulative incidence of onset of or worsening
to Grade 3 or 4 liver toxicity compared to baseline. Dashed line is
cumulative incidence of onset or worsening of any grade liver toxicity
compared to baseline.
were reversible and not clinically significant. In our study, the onset
of symptomatic (Grade 2) hypothyroidism at 2 years post-therapy
was only 12 ± 4%, while worsening of thyroid function of any
degree occurred in 40 ± 7% of children by 2 years after 131I-MIBG
therapy. Elevations of liver function tests were more common, with
elevations to Grade 3 or 4 seen in 23 ± 5% of patients by 2 years.
The liver toxicity, however, was significantly confounded by other
contributing conditions, including other therapies, infections, and
disease progression. Out of the 136 patients evaluated for liver tox-
icity, only 8 had early 131I-MIBG-related Grade 3 and/or Grade
4 hepatic toxicity, without other concomitant conditions, almost
always transient.
Due to some dissociation of 131I-MIBG, free iodide contamina-
tion of the product, and the biologic degradation of 131I-MIBG by
the liver, free radioiodide is released and may be taken up by the
thyroid gland, leading to radiation damage [21,33]. In order to pre-
vent damage to the thyroid, stable, non-radioactive iodide ion such
as potassium iodide is administered to patients prior to 131I-MIBG
therapy to pre-saturate the thyroid. However, based on a study by
Picco et al. [22], primary hypothyroidism occurred in 12/14 patients
after 131I-MIBG therapy, typically within 6–12 months of adminis-
tration, despite using potassium iodide as a thyroid blocking agent.
In another study of 10 patients conducted by Brans et al. [23], 40%
of patients developed hypothyroidism after a mean follow-up time
of 11 months, indicating that potassium iodide administration alone
was inadequate to protect the thyroid. H.M. van Santen et al. sim-
ilarly concluded in a separate study that using potassium iodide
only for radiation protection of the thyroid gland during 131I-MIBG
treatment in children was less effective than expected. In van San-
ten’s study, up to 64% of 42 children with neuroblastoma treated
with 131I-MIBG (median three therapies) developed TSH elevation,
indicating thyroid dysfunction, after an average of 2.3 years [21].
To decrease hypothyroidism in patients who receive 131I-MIBG
therapy, van Santen conducted another study using a combination
of thyroxine, methimazole, and potassium iodide for thyroid protec-
tion and demonstrated that this combination appeared more effective
than using potassium iodide alone. With the combination of thyrox-
ine, methimazole, and potassium iodide, the hypothyroidism rate in
23 patients with median follow-up of 19 months dropped to 14%
thyroid dysfunction following 131I-MIBG therapy [20].
Using CTC v.3 criteria, the results of our study revealed a
40 ± 7% cumulative incidence rate of onset or worsening of thy-
roid toxicity of any grade at 2 years after 131I-MIBG therapy in the
patients who used a thyroid protection regimen of both potassium
iodide and potassium perchlorate. The cumulative incidence rate of
onset of or worsening to symptomatic hypothyroidism alone was
12 ± 4%. Using thyroid toxicity evaluation criteria similar to that of
Picco and van Santen who both used elevated TSH to determine thy-
roid toxicity in their studies, our study showed 12 out of 122 patients
with normal baseline thyroid function presented with Grade 1 com-
pensated hypothyroidism after 131I-MIBG therapy, and 3 out of
122 patients required hormone replacement therapy after treatment,
including 1 patient with a family history of hypothyroidism.
The most significant difference between prior studies and the cur-
rent study was the thyroid blocking regimen used before and after
131I-MIBG treatment. Rather than using potassium iodide alone or in
combination with thyroxine and methimazole, prolonged 6 weeks of
administration of potassium iodide was used with 5 days of potas-
sium perchlorate in all six clinical trials reviewed for this study.
Based on the decreased incidence of symptomatic hypothyroidism
observed in this study, the combination of potassium iodide and
potassium perchlorate appears to be more effective than most of
the previously used regimens in protecting the thyroid from 131I-
MIBG therapy. However, even with the use of potassium iodide
and potassium perchlorate, 29% of patients with evaluable imme-
diate post-therapy scans showed definite or strong thyroid uptake,
and 19% of patients showed faint thyroid uptake. However, none of
the three patients with normal baseline who were treated with L-
thyroxine post-therapy had definite or intense thyroid uptake on
their post-therapy scans. Cox regression analyses did not reveal
significant association between thyroid uptake and the cumula-
tive incidence of onset or worsening of thyroid toxicity (Table II).
This is consistent with van Santen, who also reported no corre-
lation between thyroid dysfunction and thyroid visualization after
131I-MIBG administration.
Pediatr Blood Cancer DOI 10.1002/pbc
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In addition to the thyroid blocking regimen, the lower rate of
hypothyroidism reported in this study may also be attributed to a
shorter median time from 131I-MIBG therapy to thyroid function
follow-up, and a lower median number of therapies. While other
studies report the appearance of thyroid dysfunction half a year or
more after 131I-MIBG treatment, the median time to follow-up for
this study was 3.5 months. However, 36 patients in this study were
followed for more than 1 year. In addition, in only two of the patients
who developed asymptomatic elevation of TSH did this occur more
than 1 year post-therapy; for the three patients with both elevated
TSH and low T4, including two who required hormone therapy,
the abnormality developed <6 months after 131I-MIBG treatment.
Because the patient population consisted of refractory or relapsed
neuroblastoma patients, many patients either moved on to another
therapy shortly after 131I-MIBG treatment or died, which limited
the amount of long-term endocrine data collected and available for
analysis.
A number of patients (n = 38; 24%) presented with abnormal
thyroid function at baseline. This baseline abnormality may again
have had to do with the study population, which included a major-
ity of patients who had already been heavily pre-treated prior to
131I-MIBG therapy. Non-thyroidal illnesses that cause transient dis-
ruption in thyroid function may have also played a role in some of
the aberrant thyroid functions collected at baseline and may have
contributed to some of the thyroid function abnormalities seen after
131I-MIBG therapy [34]. Family history and the effects of prior ther-
apy, as well as other treatments received after 131I-MIBG therapy,
such as IL-2 or neck irradiation, also may have been contributory
factors to thyroid function abnormalities.
Overall, the prophylactic regimen of potassium iodide and potas-
sium perchlorate with 131I-MIBG therapy is an effective method of
protecting the thyroid, resulting in a low incidence rate of clini-
cally significant hypothyroidism. Long-term multi-year follow-up
of patients receiving 131I-MIBG will be necessary as this therapy
is moved to front-line to determine if thyroid cancer, as yet unre-
ported, is also a risk, as this is a known late consequence of radiation
therapy to the neck or whole body [35,36].
The liver is also a target organ for 131I-MIBG concentration [37].
Uptake within the organ has been consistently shown on conjugate
planar imaging and one-third of injected 131I-MIBG is found within
the liver following diagnostic and therapeutic doses. 131I-MIBG is
uniformly taken up by the liver, reaching maximum uptake within
15 min after an intravenous injection of 131I-MIBG, and is rapidly
eliminated. Therefore, hepatic toxicity following 131I-MIBG therapy
has been closely monitored in neuroblastoma patients. Although
symptomatic hepatic toxicity has not been reported in patients
receiving single agent 131I-MIBG dosing <12 mCi/kg, there is less
information on the effect of 131I-MIBG exposure to the liver for
patients receiving ≥12 mCi/kg of 131I-MIBG [32,38,39]. A recent
dosimetry study supports the lack of toxicity seen in our study, as
it showed that giving 18 mCi/kg of 131I-MIBG results in <30 Gy of
radiation to the liver, below liver toxicity range [39].
Liver function abnormalities following 131I-MIBG therapy were
more prevalent than thyroid function abnormalities, with 76 ± 4% of
patients experiencing onset or worsening of hepatic toxicity of any
grade. Of these patients, only 23 ± 5% experienced Grade 3 and/or
4 liver function abnormalities by 2 years after 131I-MIBG therapy.
However, 13 of 21 cases with onset or worsening of Grade 3 and/or
4 liver toxicity were deemed unlikely related to 131I-MIBG therapy
and attributed to another etiology. Therefore, <10% of patients with
evaluable post-therapy liver data had Grade 3 and/or 4 liver toxicity
that was possibly attributed to their 131I-MIBG therapy.
Patients with Grade 3 and 4 liver toxicity who did not die shortly
after due to progressive disease had their normalization of liver
function after a median of 15 days. There were no cases of long-
term hepatic complications related to liver function elevation after
131I-MIBG therapy. Grade 1 and 2 liver toxicities attributable to 131I-
MIBG therapy were transient in patients with extended follow-up
information and resolved without intervention.
Although age, gender, and the number of prior cancer treatments
were not significantly associated with worsening of hepatic func-
tion, a strong correlation was seen between patient baseline liver
function and the onset or worsening of any grade liver toxicity. In
our analysis, the relative risk of onset of or worsening to Grade 3 or
4 hepatic toxicity after 131I-MIBG therapy showed a non-significant
but positive association with baseline grade, but the relative risk
of any onset or worsening of hepatic toxicity was significantly and
negatively associated with baseline grade. The latter result suggests
that worsening of toxicity by 1 grade level is more likely in patients
with normal liver function than for patients with Grade 1 or 2 toxic-
ity at baseline. This apparent paradox may be a result of the fact that
so many factors may cause mild elevation of transaminase levels,
such as antibiotics and other medications or infections.
In conclusion, the prophylactic regimen of potassium iodide
and potassium perchlorate with 131I-MIBG therapy is an effective
thyroid blocking regimen, with a relatively low incidence rate of
symptomatic hypothyroidism when compared to prior studies. Liver
abnormalities following 131I-MIBG therapy are primarily transient
and do not appear to pose a long-term threat to children who receive
131I-MIBG therapy for neuroblastoma. Therefore, 131I-MIBG ther-
apy is a promising treatment for children with refractory or relapsed
neuroblastoma with a relatively low rate of significant late thyroid
or hepatic dysfunction.
ACKNOWLEDGMENTS
This study was supported in part by NIH grants NCI R21
CA97758, NCI PO1 81403, NCRR UCSF-CTSI UL1 RR024131,
and the Dougherty Foundation, Alex’s Lemonade Stand Founda-
tion, Campini Foundation, V-Foundation, Mildred V. Strouss Chair,
Conner Fund, and Ciesam Foundation.
REFERENCES
1. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results
for children with high-risk neuroblastoma treated on a randomized
trial of myeloablative therapy followed by 13-cis-retinoic acid: A
Children’s Oncology Group study. J Clin Oncol 2009;27:1007–
1013.
2. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect
of disease sites, age, and prior therapy on response to iodine-131-
metaiodobenzylguanidine therapy in refractory neuroblastoma.
J Clin Oncol 2007;25:1054–1060.
3. Garaventa A, Bellagamba O, Lo Piccolo MS, et al. 131I-
metaiodobenzylguanidine (131I-MIBG) therapy for residual
neuroblastoma: A mono-institutional experience with 43 patients.
Br J Cancer 1999;81:1378–1384.
4. Matthay KK, DeSantes K, Hasegawa B, et al. Phase I dose esca-
lation of 131I-metaiodobenzylguanidine with autologous bone
marrow support in refractory neuroblastoma. J Clin Oncol
1998;16:229–236.
Pediatr Blood Cancer DOI 10.1002/pbc
Thyroid and Hepatic Function After 131I-MIBG 201
5. Lashford LS, Lewis IJ, Fielding SL, et al. Phase I/II study of iodine
131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A
United Kingdom Children’s Cancer Study Group investigation. J
Clin Oncol 1992;10:1889–1896.
6. Voute PA, Hoefnagel CA, de Kraker J, et al. Results of treatment
with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with
neuroblastoma. Future prospects of zetotherapy. Prog Clin Biol Res
1991;366:439–445.
7. Lumbroso J, Hartmann O, Schlumberger M. Therapeutic use
of [131I]metaiodobenzylguanidine in neuroblastoma: A phase
II study in 26 patients. “Societe Francaise d’Oncologie Pedi-
atrique” and Nuclear Medicine Co-investigators. J Nucl Biol Med
1991;35:220–223.
8. Klingebiel T, Feine U, Treuner J, et al. Treatment of neuroblas-
toma with [131I]metaiodobenzylguanidine: Long-term results in
25 patients. J Nucl Biol Med 1991;35:216–219.
9. Hutchinson RJ, Sisson JC, Miser JS, et al. Long-term results of
[131I]metaiodobenzylguanidine treatment of refractory advanced
neuroblastoma. J Nucl Biol Med 1991;35:237–240.
10. DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine
for the treatment of neuroblastoma. Nucl Med Biol 2008;35:S35–
S48.
11. Matthay KK, Tan JC, Villablanca JG, et al. Phase I dose esca-
lation of iodine-131-metaiodobenzylguanidine with myeloablative
chemotherapy and autologous stem-cell transplantation in refrac-
tory neuroblastoma: A new approaches to Neuroblastoma Therapy
Consortium Study. J Clin Oncol 2006;24:500–506.
12. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-
131-metaiodobenzylguanidine in combination with myeloablative
chemotherapy and autologous stem-cell support for the treatment
of neuroblastoma. J Clin Oncol 2002;20:2142–2149.
13. Klingebiel T, Bader P, Bares R, et al. Treatment of neurob-
lastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose
chemotherapy and immunotherapy. A pilot study. Eur J Cancer
1998;34:1398–1402.
14. Mastrangelo S, Tornesello A, Diociaiuti L, et al. Treatment of
advanced neuroblastoma: Feasibility and therapeutic potential
of a novel approach combining 131-I-MIBG and multiple drug
chemotherapy. Br J Cancer 2001;84:460–464.
15. Gaze MN, Chang YC, Flux GD, et al. Feasibility of dosimetry-
based high-dose 131I-meta-iodobenzylguanidine with topotecan as
a radiosensitizer in children with metastatic neuroblastoma. Cancer
Biother Radiopharm 2005;20:195–199.
16. Hoefnagel CA, De Kraker J, Valdes Olmos RA, et al. 131I-MIBG
as a first-line treatment in high-risk neuroblastoma patients. Nucl
Med Commun 1994;15:712–717.
17. DuBois SG, Messina J, Maris JM, et al. Hematologic toxic-
ity of high-dose iodine-131-metaiodobenzylguanidine therapy for
advanced neuroblastoma. J Clin Oncol 2004;22:2452–2460.
18. Hoefnagel CA, Voute PA, De Kraker J, et al. [131I]metaiodo-
benzylguanidine therapy after conventional therapy for neuroblas-
toma. J Nucl Biol Med 1991;35:202–206.
19. van Santen HM, de Kraker J, Vulsma T. Endocrine late effects
from multi-modality treatment of neuroblastoma. Eur J Cancer
2005;41:1767–1774.
20. van Santen HM, de Kraker J, van Eck BL, et al. Improved radiation
protection of the thyroid gland with thyroxine, methimazole, and
potassium iodide during diagnostic and therapeutic use of radio-
labeled metaiodobenzylguanidine in children with neuroblastoma.
Cancer 2003;98:389–396.
21. van Santen HM, de Kraker J, van Eck BL, et al. High incidence
of thyroid dysfunction despite prophylaxis with potassium iodide
during (131)I-meta-iodobenzylguanidine treatment in children with
neuroblastoma. Cancer 2002;94:2081–2089.
22. Picco P, Garaventa A, Claudiani F, et al. Primary hypothyroidism
as a consequence of 131-I-metaiodobenzylguanidine treatment for
children with neuroblastoma. Cancer 1995;76:1662–1664.
23. Brans B, Monsieurs M, Laureys G, et al. Thyroidal uptake and
radiation dose after repetitive I-131-MIBG treatments: Influence
of potassium iodide for thyroid blocking. Med Pediatr Oncol
2002;38:41–46.
24. Modak S, Pandit-Taskar N, Kushner BH, et al. Transient siaload-
enitis: A complication of 131I-metaiodobenzylguanidine therapy.
Pediatr Blood Cancer 2008;50:1271–1273.
25. Weiss B, Vora A, Huberty J, et al. Secondary myelodysplastic
syndrome and leukemia following 131I-metaiodobenzylguanidine
therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol
2003;25:543–547.
26. Garaventa A, Gambini C, Villavecchia G, et al. Second malignan-
cies in children with neuroblastoma after combined treatment with
131I-metaiodobenzylguanidine. Cancer 2003;97:1332–1338.
27. Matthay KK, Quach A, Huberty J, et al. Iodine-131–
metaiodobenzylguanidine double infusion with autologous stem-
cell rescue for neuroblastoma: A new approaches to neuroblastoma
therapy phase I study. J Clin Oncol 2009;27:1020–1025.
28. Matthay KK, Panina C, Huberty J, et al. Correlation of tumor
and whole-body dosimetry with tumor response and toxicity in
refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med
2001;42:1713–1721.
29. Kim HT. Cumulative incidence in competing risks data and com-
peting risks regression analysis. Clin Cancer Res 2007;13:559–
565.
30. Cox DRaDO. Analysis of survival data. New York: Chapman and
Hall; 1984.
31. StataCorp. “Stata Statistical Software” Release 9. 2005. College
Station, TX: StataCorp. LP; 2005.
32. Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial
of the hu14.18-IL2 (EMD 273063) as a treatment for children with
refractory or recurrent neuroblastoma and melanoma: A study of
the Children’s Oncology Group. Clin Cancer Res 2006;12:1750–
1759.
33. Wafelman AR, Hoefnagel CA, Maes RA, et al. Radiochemical
purity, at expiry, and radiochemical stability of iodine-131 labelled
meta-iodobenzylguanidine concentrates for intravenous infusion.
Nuklearmedizin 1996;35:122–125.
34. Warner MH, Beckett GJ. Mechanisms behind the non-thyroidal
illness syndrome: An update. J Endocrinol 2010;205:1–13.
35. Acharya S, Sarafoglou K, LaQuaglia M, et al. Thyroid neoplasms
after therapeutic radiation for malignancies during childhood or
adolescence. Cancer 2003;97:2397–2403.
36. Papadopoulou F, Efthimiou E. Thyroid cancer after external or
internal ionizing irradiation. Hell J Nucl Med 2009;12:266–270.
37. Nakajo M, Shapiro B, Copp J, et al. The normal and
abnormal distribution of the adrenomedullary imaging agent m-
[I-131]iodobenzylguanidine (I-131 MIBG) in man: Evaluation by
scintigraphy. J Nucl Med 1983;24:672–682.
38. Jacobsson LMS, Johansson L, Lindberg S, et al. Biokinetics and
dosimetry of 131-I-metaiodobenzylguanidine (MIBG). Proceeding
of Fourth International Radiopharmaceutical Dosimetry Sympo-
sium, Oak Ridge, TN; 1985.
39. Koral KF, Huberty JP, Frame B, et al. Hepatic absorbed radiation
dosimetry during I-131 metaiodobenzylguanidine (MIBG) ther-
apy for refractory neuroblastoma. Eur J Nucl Med Mol Imaging
2008;35:2105–2112.
Pediatr Blood Cancer DOI 10.1002/pbc
